Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2026)

Lyell Immunopharma's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 32.23% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $10.4 million (down 42.21% YoY), while the FY2025 annual figure was $11.5 million, down 41.22% from the prior year.
• Depreciation & Amortization (CF) came in at $2.3 million for Q1 2026 at Lyell Immunopharma, down from $2.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.1 million in Q3 2023 to a low of $2.3 million in Q1 2026.
• A 5-year average of $4.2 million and a median of $4.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 113.84% in 2022 and tumbled 52.31% in 2025, its largest moves.
• Lyell Immunopharma's Depreciation & Amortization (CF) stood at $5.0 million in 2022, then grew by 0.32% to $5.1 million in 2023, then retreated by 0.61% to $5.0 million in 2024, then sank by 52.31% to $2.4 million in 2025, then declined by 2.71% to $2.3 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.3 million, $2.4 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison